Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTIV-4A Antithrombotics in COVID-19
NCT04505774Phase 4Completed
- Start
- Sep 2020
- Primary completion
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 4, randomised, open-label trial of heparin and crizanlizumab in coronavirus disease 2019 (COVID-19) (8 arms). Primary endpoint: 21 Day Organ Support (Respiratory or Vasopressor) Free Days. Started Sep 2020; status: completed.
02
Drugs
heparincrizanlizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04505774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04505774.